AbbVie Inc.
NOT FOUND
▼
-0.43%
2026-04-22 10:12:13
www.abbvie.com
NYQ: ABBV
Explore AbbVie Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$360.82 B
Current Price
NOT FOUND
52W High / Low
$244.81 / $168.54
Stock P/E
86.59
Book Value
$-1.85
Dividend Yield
3.4%
ROCE
22.16%
ROE
62.25%
Face Value
—
EPS
$2.36
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
57,000
Beta
0.36
Debt / Equity
-20.64
Current Ratio
0.67
Quick Ratio
0.56
Forward P/E
12.92
Price / Sales
6.01
Enterprise Value
$430.86 B
EV / EBITDA
14.73
EV / Revenue
7.04
Rating
Buy
Target Price
$248.79
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Strong operating margin profile.
- Meaningful dividend yield is available.
Cons
- Current ratio suggests tighter short-term liquidity.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Novo Nordisk A/S | $39.12 | 10.82 | $131.02 B | 4.54% | 39.01% | 60.7% | $533.4 / $224.25 | $6.83 |
| 2. | Bristol-Myers Squibb Company | $59.38 | 17.16 | $121.36 B | 4.26% | 20.6% | 40.44% | $62.89 / $42.52 | $9.07 |
| 3. | Gilead Sciences, Inc. | $133.45 | 19.68 | $165.41 B | 2.41% | 24.79% | 40.66% | $157.29 / $93.37 | $18.29 |
| 4. | Novartis AG | $147.76 | 20.66 | $301.93 B | 3.13% | 21.09% | 30.81% | $131 / $87.89 | $24.18 |
| 5. | Eli Lilly and Company | $921 | 40.12 | $868.52 B | 0.75% | 38.44% | 1.01% | $1,133.95 / $623.78 | $29.66 |
| 6. | Scilex Holding Company | $6.95 | — | $58.97 M | — | 55.67% | 39.83% | $34.27 / $3.6 | $-29.75 |
| 7. | Organon & Co. | $9.26 | 12.89 | $2.41 B | 0.86% | 11.7% | 30.56% | $13.24 / $5.69 | $2.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 16.62 B | 15.78 B | 15.42 B | 13.34 B | 15.1 B |
| Operating Profit | 5.81 B | 4.58 B | 5.72 B | 3.98 B | 84 M |
| Net Profit | 1.82 B | 186 M | 938 M | 1.29 B | -22 M |
| EPS in Rs | 1.03 | 0.11 | 0.53 | 0.73 | -0.01 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 61.16 B | 56.33 B | 54.32 B | 58.05 B |
| Operating Profit | 20.09 B | 11.89 B | 13.54 B | 18.81 B |
| Net Profit | 4.23 B | 4.28 B | 4.86 B | 11.84 B |
| EPS in Rs | 2.39 | 2.42 | 2.75 | 6.69 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 133.96 B | 135.16 B | 134.71 B | 138.81 B |
| Total Liabilities | 137.19 B | 131.8 B | 124.31 B | 121.52 B |
| Equity | -3.27 B | 3.33 B | 10.36 B | 17.25 B |
| Current Assets | 29.06 B | 25.58 B | 33 B | 28.46 B |
| Current Liabilities | 43.29 B | 38.75 B | 37.84 B | 29.54 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 19.03 B | 18.81 B | 22.84 B | 24.94 B |
| Investing CF | -6.64 B | -20.82 B | -2.01 B | -623 M |
| Financing CF | -12.72 B | -5.21 B | -17.22 B | -24.8 B |
| Free CF | 17.82 B | 17.83 B | 22.06 B | 24.25 B |
| Capex | -1.21 B | -974 M | -777 M | -695 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 8.57% | 3.71% | -6.44% | — |
| Earnings Growth % | -1.22% | -12.03% | -58.91% | — |
| Profit Margin % | 6.91% | 7.59% | 8.95% | 20.39% |
| Operating Margin % | 32.85% | 21.11% | 24.92% | 32.41% |
| Gross Margin % | 70.24% | 69.99% | 62.42% | 70% |
| EBITDA Margin % | 28.82% | 26.47% | 31.61% | 41.64% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-01-16 | $1.73 |
| 2025-10-15 | $1.64 |
| 2025-07-15 | $1.64 |
| 2025-04-15 | $1.64 |
| 2025-01-15 | $1.64 |
Stock Splits
No stock split history available.